Officially announced on February 24, 2021 that our stock name will be changed from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’ as of March 2, 2021.
This change aims “to standardize our stock name with Prestige Biologics Co., Ltd. scheduled to be listed on KOSDAQ next month and provide a clear understanding of each company’s business areas”
Prestige Biopharma (PB PHARMA) is a Singapore-based biopharmaceutical company focusing on the development of biosimilars and new antibody therapeutics.
Its lead program, HD201 trastuzumab biosimilar, has been filed with the EMA in 2019 and will also be filed with the USFDA in 2021.
Prestige BioPharma's next products in line include a Bevacizumab biosimilar (HD204) in Phase III,
an Adalimumab biosimilar (PBP1502) IND-ready for Phase I and an innovative anti-PAUF mAb (PBP 1510) for the treatment of pancreatic cancer also
IND-ready for Phase I/IIa. Manufacturing facilities for global commercial supply are located in Osong, South Korea.